Date: 2012-11-13
Type of information: R&D agreement
Compound: novel Galectin-3 inhibitors
Company: Galecto Biotech (Sweden) Edinburgh BioQuarter (UK)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease: fibrosis
Details: Edinburgh BioQuarter has completed negotiations for a collaboration between scientists working at the University of Edinburgh’s College of Medicine and Veterinary Medicine and Galecto Biotech of Sweden, a spin-out from the University of Lund. The new collaboration will develop a series of novel Galectin-3 inhibitors as a treatment for fibrosis. Galectin-3 inhibitors may inhibit the processes which drive tissue fibrosis. Project leaders at the University of Edinburgh are Dr Neil Henderson and Dr Alison MacKinnon and researchers at Kings’ College London and Lund University will also be involved in the development of these treatments.
Financial terms:
Latest news:
